# Tianci International Pharmaceutical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tianci-international-pharmaceutical

- Industry: Pharmaceuticals
- Headquarters: Shanghai, China
- Website: www.wepharma.cn
- Latest round: Series C (Dec 24, 2015)
- Investors on record: 2

## About

Establishd in 2013 and based in Shanghai, China, Tianci International Pharmaceutical operates as a pharmaceutical industry chain aggregation platform that focuses on drug research and development technical support. In March 2017, the company closed a round of series D funding.

The company focuses on the research and development of new drugs and APIs. The products mainly include innovative drugs and generic drugs. Innovative drugs include therapeutic biological products, Class 1 innovative thrombolytic drugs HTUPA, IDO inhibitors, and mannooligosaccharide diacid capsules. The generic drug is amlodipine besylate tablets, which are used to treat cardiovascular diseases such as hypertension and coronary heart disease.

The company generates revenue by providing new drugs and APIs.

## Funding rounds

- Series C, Dec 24, 2015 — GTJA Innovation Investment, Haisi Chuanzong Investment Management

## Investors

- GTJA Innovation Investment (https://capitalatlas.ai/funds/gtja-innovation-investment) — Series C
- Haisi Chuanzong Investment Management (https://capitalatlas.ai/funds/haisi-chuanzong-investment-management) — Series C